Roflumilast: Beneficios, Usos y Efectos Secundarios del Tratamiento #Roflumilast #SaludRespiratoria #Medicamentos
Arcutis Shows Positive Infant Roflumilast Data: Arcutis (Nasdaq: ARQT) presented infant roflumilast data reported Mar 28, 2026; full dataset and regulatory intent will determine commercial and valuation… 👈 Read full analysis #Arcutis #Roflumilast #PediatricDermatology #InfantHealth #ClinicalTrials
New findings suggest topical #roflumilast 0.3% significantly improves #psoriasis outcomes, including IGA and PASI scores, compared to placebo.
The systematic review and meta-analysis involved five RCTs with 1835 participants.
View more:
New from the FDA:
The agency accepts Arcutis Biotherapeutics' sNDA application for #roflumilast cream 0.3% (Zoryve) to treat #plaque #psoriasis in children aged 2 to 5 years. #medsky #pedsky
More details to come on contemporarypediatrics.com.
Arcutis Biotherapeutics has announced the commercial launch of #roflumilast 0.05% for the treatment of mild-to-moderate atopic dermatitis in children aged 2 to 5 years.
Arcutis stated the topical formulation will be available in pharmacies this week.
www.contemporarypediatrics.com/view/lawrenc...
View a quick recap of data along with multiple comments from health care professionals on how #roflumilast can help children with the scalp and body #psoriasis. #Medsky #Pedsky
Read more: www.contemporarypediatrics.com/view/reactio...